Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)], By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022

Description: Currently, Immu-no-oncology market has witnessed a high number of advancements. The competition between the players is intensifying. The biotechnology and pharmaceutical companies are striving to achieve first mover advantage by launching new and most effective therapies. This therapy is expected to be a game-changing approach to treating cancer.

The report “Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)], By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022” provides a detailed analysis of the current and future market scenario of the global Immuno-oncology market with a brief overview of the industry. The report also provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global Immuno-oncology market.

According to this edition of the report, the Immuno-oncology market is anticipated to hit billions of dollars within the next 5-10 years. The report also provides the sales of major marketed Immuno-oncology drugs.

On the basis of type of product, the global Immuno-oncology market has been segmented into major product classes including monoclonal antibodies, therapeutic vaccines, and immune checkpoint inhibitors amongst others. According to the report, monoclonal antibodies segment was estimated to account for the largest share in 2016 due to rising prevalence of cancer & rising usage in a number of therapies (antibody-directed enzyme prodrug therapy and radio immunotherapy). Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America was estimated to account for the largest share.

Primarily, the Immuno-oncology market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immuno-oncology market. The report provides the market analysis of major indications along with the forecast till 2022.

Moreover, a major focus has been on the ongoing clinical trials for the development of innovative products. In this context, we have provided information about the Immuno-oncology programs at various stages of clinical development. The study also provides a comprehensive overview of various aspects of the clinical trials in the Immuno-oncology market, such as phases, and product type. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.

The latter part of the report discusses some of the prominent players in the Immuno-oncology market. Some of the key players dominant in the market are Amgen, Bristol-Myers Squibb, F. Hoffmann-La Roche, and Merck among others. A brief business overview of each player has been provided, along with their product and pipeline portfolios and recent developments.

Overall, Immuno-oncology is an important and rapidly emerging field, which deserves the attention it has been receiving in recent years; and thus the report will prove as a complete source of knowledge and analysis for clients and potential investors.

Contents:

1. Analyst View
2. Research Methodology
3. Immuno-Oncology: Overview
4. Market Drivers & Challenges
4.1 Drivers
   4.1.1 Increasing Cancer Incidences
   4.1.2 Immune Checkpoint Inhibitors Sales Driving the Market Growth
   4.1.3 Growing Geriatric Population
   4.1.4 High Healthcare Spending In Developed Economies
   4.1.5 Strong Pipeline
   4.1.6 Increasing Efficacy in a Wide Variety of Indications
   4.1.7 Burgeoning Approval and Uptake of Immuno-Oncology Products
4.2 Challenges
   4.2.1 Patent Expiry of Top-Selling Drugs
   4.2.2 Increasing Number of Side-Effects Post Immunotherapy Treatments
   4.2.3 Sky-High Development Costs of Cancer Immunotherapies
   4.2.4 High Cost of Treatment
   4.2.5 Lack of Awareness
4.3 Opportunities
   4.3.1 Opdivo and Keytruda Presents Significant Growth Opportunity
   4.3.2 Combination Therapies Could Lead to Substantial Increases in Survival
   4.3.3 CAR-T Therapies: The Future of Cancer Care
   4.3.4 Small Companies Offering Huge Opportunities for Next Generation Immunotherapies

5. Global Immuno-Oncology Market Outlook 2022

6. Global Immuno-Oncology Market, by Product Class
   6.1 Monoclonal Antibodies (mAbs)
      6.1.1 Naked Monoclonal Antibodies
         6.1.1.1 Avastin (Bevacizumab)
         6.1.1.2 Herceptin (Trastuzumab)
      6.1.2 Conjugated Monoclonal Antibodies
         6.1.2.1 ADCETRIS (Brentuximab vedotin)
         6.1.2.2 Kadcyla (Ado-trastuzumab emtansine/TDM-1)
      6.1.3 Bispecific Monoclonal Antibodies
         6.1.3.1 Blincyto (Blinatumomab)
      6.1.4 Others
   6.2 Therapeutic Vaccines
      6.2.1 Provenge
      6.2.2 Pediarix/Infanrix
   6.3 Immune Checkpoint Inhibitors
      6.3.1 CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4)
         6.3.1.1 Yervoy (Ipilimumab)
      6.3.2 PD-1 and PD-L1 Inhibitors (Programmed Death 1 and Programmed Death Ligand
         6.3.2.1 Opdivo (Nivolumab)
         6.3.2.2 Keytruda (Pembrolizumab)
   6.4 Others

7. Global Immuno-Oncology Market, By Major Indications
   7.1 Head & Neck Cancer
   7.2 Lung Cancer
   7.3 Melanoma
   7.4 Lymphoma
   7.5 Leukemia
   7.6 Others

8. Global Immuno-Oncology Market, By Geography
   8.1 North America
   8.2 Europe
   8.3 Asia-Pacific

9. Trends & Developments
   9.1 Lucrative Investment Trend
   9.2 Emergence of Targeted and Combination Therapies
   9.3 NSCLC & Melanoma Showing Greatest Contributions to the IO Market
9.4 Bristol-Myers Squibb and Merck & Co: Top Immuno-Oncology Dealmakers

10. Strategic Collaborations & Alliances in the Immuno-Oncology Industry

11. Pipeline Analysis of Immuno-Oncology

12. Competitive Landscape
   12.1 Share of Major Players

13. Key Players Analysis
   13.1 F. Hoffmann-La Roche AG
   13.2 Johnson & Johnson
   13.3 Amgen Inc.
   13.4 Celgene Corporation
   13.5 Bristol-Myers Squibb
   13.6 Merck & Co., Inc.
   13.7 Novartis
   13.8 AstraZeneca Plc
   13.9 Pfizer Inc
   13.10 Eli Lilly and Company

List of Figures:

Figure 4-1: Global - Cancer Incidences (Million), 2015, 2020, 2025 & 2030
Figure 4-2: Global - Cancer Mortality (Million), 2015, 2020, 2025 & 2030
Figure 4-3: Global - Population above 60 Years (Billion), 2015 & 2050
Figure 5-1: Global - Immuno-Oncology Market (Billion US$), 2016-2022
Figure 6-1: Global - Share of Immuno-Oncology Market by Product (%), 2016
Figure 6-2: Global - Share of Immuno-Oncology Market by Product (%), 2022
Figure 6-3: Global - Monoclonal Antibodies Market (Billion US$), 2016-2022
Figure 6-4: Global - Avastin Market (Billion US$), 2012-2015
Figure 6-5: Global - Herceptin Market (Billion US$), 2012-2015
Figure 6-6: Global - ADCETRIS Market (Million US$), 2012-2015
Figure 6-7: Global - Kadcyla Market (Billion US$), 2013-2016
Figure 6-8: Global - Blincyto Market (Million US$), 2014-2016
Figure 6-9: Global - Other Monoclonal Antibodies Market (Billion US$), 2016-2022
Figure 6-10: Global - Therapeutic Cancer Vaccines Market (Billion US$), 2016-2022
Figure 6-11: Global - Provenge Market (Billion US$), 2012-2015
Figure 6-12: Global - Pediarix/Infanrix Market (Billion US$), 2012-2014
Figure 6-13: Global - Immune Checkpoint Inhibitors Market (Billion US$), 2016-2022
Figure 6-14: Global - Yervoy Market (Million US$), 2012-2015
Figure 6-15: Global - Opdivo Market (Billion US$), 2014-2016
Figure 6-16: Global - Keytruda Market (Billion US$), 2014-2016
Figure 6-17: Global - Others Market (Billion US$), 2016-2022
Figure 7-1: Global - Share of Immuno-Oncology Market by Application (%), 2016
Figure 7-2: Global - Share of Immuno-Oncology Market by Application (%), 2022
Figure 7-3: Global - Head & Neck Cancer Market (Billion US$), 2016-2022
Figure 7-4: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-5: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-6: Global - Lung Cancer Market (Billion US$), 2016-2022
Figure 7-7: Lung Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-8: Lung Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-9: Global - Melanoma Market (Billion US$), 2016-2022
Figure 7-10: Melanoma - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-11: Melanoma - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-12: Global - Lymphoma Market (Billion US$), 2016-2022
Figure 7-13: Lymphoma - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-14: Lymphoma - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-15: Global - Leukemia Market (Billion US$), 2016-2022
Figure 7-16: Leukemia - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-17: Leukemia - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-18: Global - Other Cancer Market (Billion US$), 2016-2022
Figure 7-19: Other Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
Table 13-7: Amgen Inc. - Financials (Billion US$), 2013-2015
Table 13-8: Amgen Inc. - Commercialized Immuno-Oncology Products
Table 13-9: Amgen Inc. - Product Pipeline
Table 13-10: Celgene Corporation - Key Financials (Million US$), 2013-2015
Table 13-11: Celgene Corporation - Commercialized Immuno-Oncology Products
Table 13-12: Celgene Corporation - Product Pipeline
Table 13-13: Bristol Myers Squibb - Key Financials (Million US$), 2013-2015
Table 13-14: Bristol Myers Squibb - Commercialized Immuno-Oncology Products
Table 13-15: Bristol Myers Squibb - Product Pipeline
Table 13-16: Merck & Co., Inc. - Key Financials (Million US$), 2013-2015
Table 13-17: Merck & Co., Inc. - Commercialized Immuno-Oncology Products
Table 13-18: Merck & Co., Inc. - Product Pipeline
Table 13-19: Novartis - Financials (Billion US$), 2013-2015
Table 13-20: Novartis - Commercialized Immuno-Oncology Products
Table 13-21: Novartis - Product Pipeline
Table 13-23: AstraZeneca Plc - Commercialized Immuno-Oncology Products
Table 13-24: AstraZeneca Plc - Product Pipeline
Table 13-25: Pfizer Inc - Key Financials (Billion US$), 2013-2015
Table 13-26: Pfizer Inc - Commercialized Immuno-Oncology Products
Table 13-27: Pfizer Inc - Product Pipeline
Table 13-28: Eli Lilly and Company - Key Financials (Million US$), 2013-2015
Table 13-29: Eli Lilly and Company - Commercialized Immuno-Oncology Products
Table 13-30: Eli Lilly and Company - Product Pipeline

Ordering:
Order Online - http://www.researchandmarkets.com/reports/4033812/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)], By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022
Web Address: http://www.researchandmarkets.com/reports/4033812/
Office Code: SC2GBNTS

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>USD 3000</td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
</tr>
<tr>
<td>Hard Copy:</td>
<td>USD 3500 + USD 56 Shipping/Handling</td>
</tr>
<tr>
<td>CD-ROM:</td>
<td>USD 3500 + USD 56 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>USD 6000</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td></td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.
* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ______________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World